S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in
(Ad)
What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%? Wall Street legend Paul Mampilly recently identified this as the stock of the century. Buying up a handful of shares of this small company now could change your life and even make you millions.

NYSE:GSK - GlaxoSmithKline Stock Price, Forecast & News

$47.79
+0.29 (+0.61 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$47.60
Now: $47.79
$47.84
50-Day Range
$45.06
MA: $46.74
$47.89
52-Week Range
$38.16
Now: $47.79
$48.22
Volume2.61 million shs
Average Volume2.33 million shs
Market Capitalization$119.20 billion
P/E Ratio20.42
Dividend Yield4.15%
Beta0.68
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$41.14 billion
Cash Flow$4.15 per share
Book Value$1.98 per share

Profitability

Net Income$4.84 billion

Miscellaneous

Employees95,490
Outstanding Shares2,494,212,000
Market Cap$119.20 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Friday, May 3rd. Shareholders of record on Friday, May 17th will be given a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 dividend on an annualized basis and a yield of 4.15%. The ex-dividend date of this dividend is Thursday, May 16th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) issued its earnings results on Wednesday, October, 30th. The pharmaceutical company reported $0.95 EPS for the quarter, topping the Zacks' consensus estimate of $0.85 by $0.10. The pharmaceutical company earned $11.57 billion during the quarter, compared to analyst estimates of $11.34 billion. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

12 analysts have issued 12-month target prices for GlaxoSmithKline's stock. Their forecasts range from $45.00 to $53.00. On average, they expect GlaxoSmithKline's share price to reach $49.00 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

News headlines about GSK stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlaxoSmithKline earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media headlines about the pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for GlaxoSmithKline.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 7,110,000 shares, an increase of 6.0% from the November 28th total of 6,710,000 shares. Based on an average daily volume of 2,680,000 shares, the short-interest ratio is presently 2.7 days. Currently, 0.3% of the company's stock are sold short. View GlaxoSmithKline's Current Options Chain.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Bank of America (BAC), Johnson & Johnson (JNJ), Intel (INTC), General Electric (GE) and Exxon Mobil (XOM).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janney Montgomery Scott LLC (0.02%), Janney Capital Management LLC (0.02%), Chemung Canal Trust Co. (0.01%), Hennessy Advisors Inc. (0.00%), Farmers Trust Co. (0.00%) and Ipswich Investment Management Co. Inc. (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Janney Capital Management LLC, Farmers Trust Co., Zeke Capital Advisors LLC, Hennessy Advisors Inc., Fluent Financial LLC, Mountain Capital Investment Advisors Inc, CENTRAL TRUST Co and Chemung Canal Trust Co.. View Insider Buying and Selling for GlaxoSmithKline.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was bought by a variety of institutional investors in the last quarter, including Mainstay Capital Management LLC ADV, Janney Montgomery Scott LLC, Boenning & Scattergood Inc., Optimum Investment Advisors, AE Wealth Management LLC, Curbstone Financial Management Corp, OLD National Bancorp IN and Ingalls & Snyder LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $47.79.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $119.20 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com/.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  695 (Vote Outperform)
Underperform Votes:  1,047 (Vote Underperform)
Total Votes:  1,742
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Cash Flow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel